Published in Eur J Nucl Med Mol Imaging on March 18, 2010
Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol (2010) 0.86
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer (2002) 3.74
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer (2003) 2.97
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med (2004) 2.16
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun (2004) 1.84
The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist (2008) 1.74
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging (2004) 1.47
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol (2007) 1.40
18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg (2005) 1.22
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res (2006) 1.07
Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res (2005) 1.01
Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am (2009) 0.93
Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol (2006) 0.93
Congestive heart failure during imatinib mesylate treatment. Int J Cardiol (2009) 0.87
The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie (2007) 0.86
FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nucl Med Commun (2008) 0.85
Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol (2007) 0.84
Metastasis in a benign duodenal stromal tumour. Eur J Surg Oncol (1998) 0.78
Diffuse intense FDG uptake in the bone marrow in gastrointestinal stromal tumor with coexistent polycythemia rubra vera. Clin Nucl Med (2008) 0.77
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging (2007) 1.93
An original case of isolated unilateral adrenal metastasis from penile carcinoma: documentation by 18F-FDG-PET imaging and histopathology. Hell J Nucl Med (2010) 1.49
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Is PET-CT the only option? Eur J Nucl Med Mol Imaging (2007) 1.48
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med (2007) 1.47
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging (2013) 1.44
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol (2009) 1.42
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat (2009) 1.42
Splinting of penis following microvascular reconstruction-A simple inexpensive method. Indian J Plast Surg (2009) 1.39
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging (2009) 1.13
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging (2007) 1.13
A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med (2009) 1.12
Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol (2009) 1.11
Underestimated role of 18F-FDG PET for HCC evaluation and promise of 18F-FDG PET/MR imaging in this setting. J Nucl Med (2013) 1.09
A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging (2011) 1.04
Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging (2007) 1.01
SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions. Eur J Nucl Med Mol Imaging (2013) 0.99
Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol (2009) 0.97
Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol (2012) 0.97
Chondroid hamartoma presenting as solitary pulmonary nodule: results of dual time point (18)F-fluorodeoxyglucose-PET and comparison with (18)F-fluorothymidine PET and histopathology. Hell J Nucl Med (2011) 0.96
Dual ectopic thyroid. Indian Pediatr (2006) 0.94
Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun (2008) 0.94
Recurrence of dermatofibrosarcoma protuberans in post-surgical scar detected by 18F-FDG-PET imaging. Hell J Nucl Med (2009) 0.93
Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma. Hell J Nucl Med (2009) 0.92
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol (2007) 0.91
Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept. Hell J Nucl Med (2011) 0.90
(18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis. Hell J Nucl Med (2012) 0.90
Optimizing interventions for preventing uptake in the brown adipose tissue in FDG-PET. Eur J Nucl Med Mol Imaging (2008) 0.90
Adverse functional effects of chemotherapy on whole-brain metabolism: a PET/CT quantitative analysis of FDG metabolic pattern of the "chemo-brain". Clin Nucl Med (2014) 0.89
Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med (2011) 0.89
A pilot study of changes in (18)F-FDG uptake, calcification and global metabolic activity of the aorta with aging. Hell J Nucl Med (2009) 0.88
Primary paraganglioma of thyroid presenting as solitary thyroid mass. J Cancer Res Ther (2011) 0.87
Functional imaging of brown adipose tissue with PET: can this provide new insights into the pathophysiology of obesity and thereby direct antiobesity strategies? Nucl Med Commun (2008) 0.86
Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach. Womens Health (Lond Engl) (2012) 0.86
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging (2013) 0.86
Fluorodeoxyglucose-positron emission tomography imaging characteristics of unusual cystic metastasis on the liver surface arising from gallbladder carcinoma. Jpn J Radiol (2009) 0.85
PET and PET/CT for unknown primary tumors. Methods Mol Biol (2011) 0.84
The effects of aging on testicular volume and glucose metabolism: an investigation with ultrasonography and FDG-PET. Mol Imaging Biol (2011) 0.84
Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol (2007) 0.83
Beta-cell imaging: opportunities and limitations. J Nucl Med (2011) 0.83
FDG uptake in unilateral breast related to breastfeeding practice in a patient of pulmonary hydatid cyst. Clin Nucl Med (2012) 0.83
Central photopenic lesions on FDG-PET scan in a patient with peripheral T cell lymphoma. Ann Nucl Med (2008) 0.82
Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol. Eur J Nucl Med Mol Imaging (2014) 0.82
Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care. Nucl Med Rev Cent East Eur (2009) 0.82
Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity? World J Radiol (2012) 0.82
Detection by (18)F-FDG PET of unsuspected extensive bone marrow metastases in a case of basosquamous carcinoma of the cheek. Hell J Nucl Med (2011) 0.82
Feasibility of automated partial-volume correction of SUVs in current PET/CT scanners: can manufacturers provide integrated, ready-to-use software? J Nucl Med (2008) 0.82
Age-related structural and functional changes in the breast: multimodality correlation with digital mammography, computed tomography, magnetic resonance imaging, and positron emission tomography. Semin Nucl Med (2007) 0.81
Evaluation of diagnostic performance of 18F-FDG-PET compared to CT in detecting potential causes of fever of unknown origin in an academic centre. Hell J Nucl Med (2011) 0.81
The effect of age, menopausal state, and breast density on (18)F-FDG uptake in normal glandular breast tissue. J Nucl Med (2010) 0.81
Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging (2008) 0.81
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging (2007) 0.80
Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol (2009) 0.80
Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET. Hell J Nucl Med (2011) 0.80
FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies. Eur J Nucl Med Mol Imaging (2006) 0.80
18F-FDG PET/CT as a sensitive and early treatment monitoring tool: will this become the major thrust for its clinical application in infectious and inflammatory disorders? J Nucl Med (2011) 0.80
Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging (2012) 0.79
Selecting the optimal image segmentation strategy in the era of multitracer multimodality imaging: a critical step for image-guided radiation therapy. Eur J Nucl Med Mol Imaging (2009) 0.79
Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med (2009) 0.79
Understanding and fighting cancer cachexia syndrome: can PET help? Nucl Med Commun (2012) 0.79
Intense FDG uptake in the spleen due to recent granulocyte-macrophage colony-stimulating factor administration: follow-up scan clarifying the situation. J Cancer Res Ther (2011) 0.79
Unsuspected metastatic male breast nodule from synovial sarcoma detected by FDG PET. Clin Nucl Med (2005) 0.79
Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET. Eur J Nucl Med Mol Imaging (2011) 0.78
Adding surgery as a complementary approach to radioiodine therapy in patients of differentiated thyroid carcinoma with large solitary flat bone metastases: the unresolved issues. J Surg Oncol (2011) 0.78
Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: will this become a clinical reality and a challenge to CT calcification scoring? Eur J Nucl Med Mol Imaging (2012) 0.78
FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach. Eur J Nucl Med Mol Imaging (2013) 0.78
Relation between popliteal-tibial artery atherosclerosis and global glycolytic metabolism in the affected diabetic foot: a pilot study using quantitative FDG-PET. J Am Podiatr Med Assoc (2012) 0.78
Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET. Eur J Nucl Med Mol Imaging (2008) 0.78
Bilateral renal metastases from papillary thyroid carcinoma on post 131I treatment scan: flip-flop sign, radioiodine SPET, 18F-FDG PET, CECT and histopathological correlation. Hell J Nucl Med (2011) 0.78
Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites? Eur J Nucl Med Mol Imaging (2007) 0.78
Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications. World J Radiol (2012) 0.78
FDG avid "abdominal band" representing omental cake in mucinous adenocarcinoma of the appendix: potential implications for disease monitoring with FDG-PET in this setting. J Cancer Res Ther (2011) 0.78
Imaging with (18)F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring. Hell J Nucl Med (2009) 0.78
Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. Eur J Nucl Med Mol Imaging (2011) 0.78
Imaging for the diagnosis of thyroid cancer. Expert Opin Med Diagn (2009) 0.78
Quantification of aging effects upon global knee inflammation by 18F-FDG-PET. Nucl Med Commun (2016) 0.77
Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Hell J Nucl Med (2010) 0.77
Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? Nucl Med Commun (2006) 0.77
Emerging role of FDG-PET for optimal response assessment in infectious diseases and disorders. Expert Rev Anti Infect Ther (2011) 0.77
Advantages of surgical extirpation in addition to radioiodine therapy in differentiated thyroid carcinoma patients with a solitary large-volume skeletal metastasis with small-volume oligometastatic disease in the rest of the whole body. J Cancer Res Ther (2013) 0.77
Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun (2014) 0.77
Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome). Nucl Med Commun (2015) 0.77
Ovarian dermoid cyst serendipitously detected by pelvic radioiodine-(131)I uptake and by diffusion weighted MRI in a post-thyroidectomy case of papillary thyroid carcinoma. Hell J Nucl Med (2013) 0.76
Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging (2013) 0.76
Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nucl Med Commun (2009) 0.76
The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study. Nucl Med Commun (2016) 0.76
Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observation. Hell J Nucl Med (2009) 0.76
Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide? Eur J Nucl Med Mol Imaging (2010) 0.76
Imaging the infected heart. Sci Transl Med (2011) 0.75
Early FDG-PET response-adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management? Eur J Nucl Med Mol Imaging (2009) 0.75
Multifaceted role of lymphatic mapping by SPECT/CT hybrid imaging in the multimodality management of patients with cancer. Eur J Nucl Med Mol Imaging (2009) 0.75
Doughnut sign on FDG-PET scan in a ruptured lung hydatid cyst. Indian J Chest Dis Allied Sci (2012) 0.75
Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans. Nucl Med Commun (2015) 0.75
Should the nuclear medicine community continue to underestimate the potential of 18F-FDG-PET/CT with present generation scanners for the diagnosis of prosthetic joint infection? Nucl Med Commun (2015) 0.75